Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03690388
Recruitment Status : Active, not recruiting
First Posted : October 1, 2018
Last Update Posted : July 15, 2021
Sponsor:
Information provided by (Responsible Party):
Exelixis

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 19, 2020
Estimated Study Completion Date : December 2022
Certification/Extension First Submitted : May 5, 2021